Table 4.
Summary of dose indices of the prostate case studies.
| ROI | Dose Index | IMRT | IMAT | AMRT | |
|---|---|---|---|---|---|
| Case 10 | PTV | * V95% | 100% | 100% | 97.3% |
| Bladder | V65 | 30.7% | 31.5% | 29.6% | |
| V75 | 18.4% | 19.8% | 11.6% | ||
| Rectum | V60 | 18.5% | 21.3% | 16.6% | |
| V70 | 8.9 % | 9.4% | 7.9% | ||
|
| |||||
| Case 11 | PTV | * V95% | 100% | 100% | 97.7% |
| Bladder | V65 | 26.5% | 27.1% | 26.5% | |
| V75 | 17.0% | 19.7% | 15.4% | ||
| Rectum | V60 | 22.5% | 24.1% | 20.6% | |
| V70 | 15.6% | 15.7% | 13.8% | ||
|
| |||||
| Case 12 | PTV | * V95% | 98.3% | 99.9% | 100% |
| Bladder | V65 | 10.1% | 11.3% | 10.5% | |
| V75 | 5.1% | 7.1% | 6.7% | ||
| Rectum | V60 | 21.9% | 20.6% | 20.2% | |
| V70 | 14.4% | 13.7% | 12.9% | ||
*
V95% is the volume of ROI receiving 95% of the prescription dose.